Drug intelligence / Profile preview

XiaoJiYin

Development stage: Preclinical
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

XiaoJiYin is a Traditional Chinese Medicine (TCM) formulation currently under clinical investigation for the treatment of advanced non-small cell lung cancer (NSCLC). It is being studied in combination with Erlotinib. Research on related formulations, such as Xiaoji decoction, suggests its mechanism of action involves inhibiting the growth of lung cancer cells through AMPKα-mediated inhibition of Sp1 and DNA methyltransferase 1. This formulation is developed by institutions specializing in Traditional Chinese Medicine and exhibits anti-tumor and anti-inflammatory properties.

Other names: Xiaoji decoction

Targets

DNMT1 (DNA (cytosine-5)-methyltransferase 1)SP1 (Transcription factor Sp1)AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on XiaoJiYin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XiaoJiYin.

Explore the full profile